18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men

Conclusion: 18F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer. These rates are comparable to previously published upstaging rates in female patients. 18F-FDG PET/CT demonstrates value for systemic staging of male patients with breast cancer and should be considered for use in newly diagnosed patients, particularly those with stage IIB and III disease.

Source: Journal of Nuclear Medicine - March 31, 2019 Category: Nuclear Medicine Authors: Ulaner, G. A., Juarez, J., Riedl, C. C., Goldman, D. A. Tags: Clinical Source Type: research